[go: up one dir, main page]

WO2015178667A1 - Utilisation de nkx6.3 pour la prévision de l'apparition du cancer et le diagnostic précoce d'un cancer et en tant qu'agent thérapeutique pour le cancer - Google Patents

Utilisation de nkx6.3 pour la prévision de l'apparition du cancer et le diagnostic précoce d'un cancer et en tant qu'agent thérapeutique pour le cancer Download PDF

Info

Publication number
WO2015178667A1
WO2015178667A1 PCT/KR2015/005013 KR2015005013W WO2015178667A1 WO 2015178667 A1 WO2015178667 A1 WO 2015178667A1 KR 2015005013 W KR2015005013 W KR 2015005013W WO 2015178667 A1 WO2015178667 A1 WO 2015178667A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
protein
expression
cell
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2015/005013
Other languages
English (en)
Korean (ko)
Inventor
박원상
윤정환
최원석
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Catholic University of Korea
Original Assignee
Industry Academic Cooperation Foundation of Catholic University of Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Catholic University of Korea filed Critical Industry Academic Cooperation Foundation of Catholic University of Korea
Priority to JP2016568505A priority Critical patent/JP6312861B2/ja
Priority claimed from KR1020150069359A external-priority patent/KR101722836B1/ko
Publication of WO2015178667A1 publication Critical patent/WO2015178667A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • the present invention relates to the use of NKX6.3 as a predictor, early diagnosis and treatment of cancer, and more particularly to early diagnosis of cancer through the amount of protein expression, mRNA expression, and DNA copy number of NKX6.3. And the use of NKX6.3 to treat cancer by administering a NKX6.3 protein or gene.
  • the gastric epithelium forms tubular branched gastric glands, which have a complex structure containing a variety of cells.
  • gastric epithelial cells have very fast cell turnover rate and induce epithelial regeneration every 3 to 5 days, but epithelial cells of gastric gland maintain homeostasis through apoptosis despite fast turnover rate.
  • Pluripotent stem cells are located in the neck or isthmus of the gastric gland, and stem cells migrate above or below the gastric gland after mitosis and differentiate into various types of cells.
  • NKX family members are known to play an important role in the development and differentiation process, such as determining the fate of cells in the central nervous system, gastrointestinal tract and pancreas.
  • NKX6.3 the third member of NKX6, a subfamily of the NKX gene, is mainly expressed in the lower / base region of epithelial cells of the gastric distal end in mouse experiments.
  • NKX6.3 is located on chromosome 8p11.21 and encodes 266 amino acid proteins.
  • NKX6.3 is expressed in mobile cells that differentiate up and down after mitosis of gastric units, and NKX6 in gastric cancer.
  • NKX6.3 Heterozygosity loss of the chromosome 8p11 region in which the gene is present is frequently observed.
  • the present inventors have found that inactivation of the NKX6.3 gene may lead to abnormal differentiation of gastric mucosal epithelial cells and imbalance of homeostasis. It was predicted that this may be a cause of adult gastritis and cancer.
  • NKX6.3 gene is related to the development of gastric cancer
  • the present inventors conducted genetic, epigenetic and expression analysis of NKX6.3 gene using 55 gastric cancer samples, and used AGS and MNK1 gastric cancer cell lines. Functional analysis was conducted. As a result, the expression of NKX6.3 was significantly decreased in gastric cancer tissues compared to normal gastric mucosal tissues, and we confirmed that NKX6.3 acts as a tumor suppressor gene that regulates the differentiation, cell proliferation and apoptosis of gastric mucosal epithelial cells. The invention has been completed.
  • An object of the present invention is to provide an anticancer composition comprising a polynucleotide encoding the NKX6.3 (NK6 homeobox3) protein or NKX6.3 protein.
  • Another object of the present invention is to predict the occurrence of cancer by confirming the expression level of NKX6.3 protein, the expression level of mRNA encoding NKX6.3 protein or the DNA copy number of NKX6.3 gene in a biological sample collected from a subject, It provides the information necessary for diagnosis or prognostic analysis.
  • It is still another object of the present invention to provide an anticancer screening method comprising the step of treating an anticancer agent to a cell and measuring the effect on the activity of NKX6.3 protein or an increase in intracellular expression level.
  • the present invention provides an anticancer composition
  • the NKX6.3 protein may be composed of the amino acid sequence of SEQ ID NO: 1.
  • the polynucleotide encoding the NKX6.3 protein may be composed of the nucleotide sequence of SEQ ID NO: 2.
  • the polynucleotide may be contained in an expression vector.
  • the cancer is breast cancer (breast cancer), liver cancer (liver cancer), bladder cancer, brain cancer (brain cancer), cervical cancer (cervical cancer), colorectal cancer (colorectal cancer), Esophageal cancer, gallbladder cancer, head and neck cancer, kidney cancer, lung cancer (small and / or non-small cell) )), Melanoma, ovarian cancer, ovary (germ cell cancer), prostate cancer, pancreatic cancer, penile cancer, skin cancer ( skin cancer, soft-tissue sarcoma, squamous cell carcinomas, stomach cancer, testicular cancer, thyroid cancer and uterine cancer One or more cancers selected.
  • the present invention is to predict the occurrence of cancer by confirming the expression amount of NKX6.3 protein, the expression amount of mRNA encoding NKX6.3 protein or the DNA copy number of NKX6.3 gene in a biological sample collected from a subject, cancer It provides a method for providing information necessary for diagnosis or prognostic analysis.
  • the biological sample for predicting cancer occurrence may be noncancerous (precancerous) tissue, and the biological sample for cancer diagnosis or prognostic analysis may be cancer tissue.
  • the noncancerous (precancerous) tissue has a reduced amount of expression of NKX6.3 protein compared to normal tissue at its periphery; The amount of expression of mRNA encoding NKX6.3 protein is decreased; Or when the DNA copy number of the NKX6.3 gene decreases; The risk of cancer is high.
  • the expression of NKX6.3 protein, Sox2 protein, and Muc5ac protein is lost in the noncancerous (precancerous) tissue, especially in the stomach, compared to normal tissues in the periphery, and Cdx2 and Muc2 If the expression of the intestinal metaplasia is in progress, it can be determined that the cancer is high.
  • the cancer tissue is reduced in the amount of expression of NKX6.3 protein compared to the normal tissue of the periphery thereof;
  • the amount of expression of mRNA encoding NKX6.3 protein is decreased; Or when the DNA copy number of the NKX6.3 gene decreases;
  • the cancer may be diagnosed or determined to be highly malignant.
  • the cancer is breast cancer (breast cancer), liver cancer (liver cancer), bladder cancer, brain cancer (brain cancer), cervical cancer (cervical cancer), colorectal cancer (colorectal cancer), Esophageal cancer, gallbladder cancer, head and neck cancer, kidney cancer, lung cancer (small and / or non-small cell) )), Melanoma, ovarian cancer, ovary (germ cell cancer), prostate cancer, pancreatic cancer, penile cancer, skin cancer ( skin cancer, soft-tissue sarcoma, squamous cell carcinomas, stomach cancer, testicular cancer, thyroid cancer and uterine cancer One or more cancers selected.
  • the present invention also provides an anticancer screening method comprising the step of treating the anticancer drug candidates to cells to determine the effect on the activity of NKX6.3 protein or an increase in intracellular expression level.
  • the candidate when the candidate increases the activity of the NKX6.3 protein or increases the expression level of the NKX6.3 gene in the cell, it may be added to determine the anticancer agent having anticancer activity Can be.
  • the activity or expression level of the NKX6.3 protein is immunoprecipitation (coimmunoprecipitation), radioimmunoassay (RIA), enzyme immunoassay (ELISA), immunohistochemistry, polymerase chain Reaction (PCR), Western blotting (Western Blotting) and flow cytometry (FACS) may be performed by any one method selected from the group consisting of.
  • NKX6.3 according to the present invention can be utilized as a diagnostic composition for early diagnosis of cancer because the activity or expression is inhibited in cancer cells, induces the expression of NKX6.3 to inhibit the survival of cancer cells and apoptosis It can be usefully used as an anti-cancer composition to exert a function of inducing and inhibiting intestinal metaplasia, which is a precancerous lesion, by inducing differentiation into gastric mucosal cells.
  • NKX6.3 shows expression of NKX6.3 in gastric cancer cell lines and gastric cancer tissues.
  • AGS, MKN1, MKN28 and MKN45 gastric cancer cell lines do not show NKX6.3 protein expression, but AGS cell lines transiently transfected with NKX6.3. Or NKX6.3 protein expression was confirmed in stably transfected AGS N6.3 and MNK1 N6.3 cell lines, B) expression of NKX6.3 protein was lost or decreased in most gastric cancer tissues, and C) Both methylated and unmethylated DNA of the NKX6.3 gene promoter region was observed in the non-cancerous gastric mucosal tissue corresponding to each example.
  • U upper stomach
  • M middle stomach, L, lower stomach
  • N normal
  • T gastric cancer
  • M methylated PCR product
  • U unmethylated PCR product
  • FIG. 2 shows NKX6.3 DNA copy number and NKX6.3 mRNA expression patterns in non-cancerous gastric mucosa and gastric cancer tissues.
  • Figure 3 shows the expression of NKX6.3 in atrophic gastritis and intestinal metaplasia of gastric mucosal tissues.
  • NKX6.3 is an expression regulator of gastric differentiation marker Sox2 and intestinal differentiation marker Cdx2,
  • A) NKX6.3 is a transcription factor by binding to the 3 ⁇ 4 kb promoter region in the Sox2 gene.
  • B) NKX6.3 increased the binding capacity as a transcription factor at the 5 kb promoter region of Cdx2 gene,
  • FIG. 5 shows that normal gastric gland in human gastric mucosal tissues expresses NKX6.3, Sox2 and Muc5ac, but gastric gland with intestinal metaplasia has lost their expression and expressed intestinal differentiation markers Cdx2 and Muc2.
  • the cell line study results were verified in human gastric mucosal tissue.
  • Figure 7 confirmed the apoptosis induction ability of NKX6.3 in AGS N6 and MNK1 N6,3 cell lines by annexin V-binding assay.
  • the present inventors have investigated the expression of NKX6.3 protein in gastric cancer tissues, taking into consideration that cancer may occur when abnormalities in cell differentiation occur. As expected, the expression of NKX6.3 is lost in gastric cancer tissues. It was confirmed that the decrease significantly.
  • NKX6.3 was not confirmed in gastric cancer cell lines such as AGS, MKN1, MKN28 and MKN45, and NKX6 was expressed in 33 (94.3%) of 35 gastric cancer tissues expressing NKX6.3 in noncancerous mucosal tissues. The expression of 3 was found to be significantly reduced or lost compared to normal tissue (see FIGS. 1A and 1B).
  • NKX6.3 decreased expression of NKX6.3 is caused by epigenetic changes in somatic cells of the NKX6.3 gene
  • mutations in the NKX6.3 gene were identified in gastric cancer tissues.
  • no somatic mutation of the NKX6.3 gene that was specific in gastric cancer tissue was identified (data not shown).
  • the present inventors analyzed the methylation to determine whether the expression of NKX6.3 is changed in gastric cancer tissue by the methylation change of the NKX6.3 gene promoter region, but methylation of the NKX6.3 gene in gastric cancer tissue and normal mucosal tissue It was confirmed that there is no significant difference (see FIG. 1C), and it was concluded that somatic mutation and promoter hypermethylation of NXK6.3 did not significantly affect the development of gastric cancer during gastric cancer development.
  • the present inventors further analyzed the DNA copy number and mRNA transcription level by real-time QPCR and real-time RT-PCR to further determine the mechanism by which NKX6.3 expression is reduced in gastric cancer, compared to non-cancerous gastric mucosal tissues.
  • DNA copy number and mRNA transcription expression in gastric cancer tissues were found to be reduced in 18 (32.7%) and 34 (61.8%) of 55 samples, respectively (see FIGS. 2A and 2B).
  • the present inventors compared the relationship between NKX6.3 DNA copy number and mRNA transcript expression, and found that there is a significant correlation between DNA copy number and mRNA transcript in both non-cancerous mucosal tissue and gastric cancer tissue. (P ⁇ 0.0001) (see FIG. 2D). From the above results, the present inventors determined that the DNA copy number and mRNA transcription level of the reduced NKX6.3 gene in gastric cancer were the main cause of the decreased expression of the NKX6.3 protein.
  • NKX6.3 is a novel transcription factor and is known to play a role in the differentiation of gastric mucosal epithelial cells.
  • the present inventors have focused on the fact that the intestinal metaplasia, which is one of the abnormalities in the cell differentiation process, is a precancerous lesion of gastric cancer, and inhibiting the intestinal metaplasia can prevent cancer, and thus the amount of NKX6.3 expression in tissues showing atrophic gastritis and enteroplastic lesions. The changes were examined. In all tissues showing atrophic gastritis and enteroplastic lesions, the expression of NKX6.3 was significantly decreased, and the expression of Cdx2 was increased (see FIG. 3).
  • NKX6.3 was evaluated for the expression of Sox2 gene, which induces differentiation into gastric mucosa, and Cdx2, which induces differentiation into intestinal mucosa. It was confirmed that the inhibition of intestinal metaplasia by adjusting.
  • NKX6.3 induces the expression of gastric differentiation marker Sox2 as a transcription factor that binds to the promoter regions of Sox2 and Cdx2 genes, while inhibiting the expression of the intestinal differentiation marker Cdx2 (see FIG. 4).
  • the present inventors observed the cell survival by constructing the AGS N6.3 and MNK1 N6.3 cell lines stably expressing NKX6.3 to determine how NKX6.3 affects the growth and death of gastric cancer cells.
  • Expression of NKX6.3 was found to inhibit time-dependent survival, cell proliferation and colony formation of these gastric cancer cell lines (see FIGS. 6A, 5B, 5C & 5D).
  • AGS NKX6.3 and MNK1 NKX6.3 cell lines induce apoptosis in these gastric cancer cell lines in a time-dependent manner (see FIG. 7). From these results, the present inventors found that NKX6.3 functions as a tumor suppressor that induces normal differentiation of gastric cancer cells, inhibits cell proliferation and controls apoptosis.
  • the present invention can provide an anticancer composition comprising a NKX6.3 protein or a polynucleotide encoding the NKX6.3 protein.
  • the NKX6.3 protein may be one having an amino acid sequence represented by SEQ ID NO: 1
  • the polynucleotide encoding the NKX6.3 protein may be one having a nucleotide sequence described in SEQ ID NO: 2.
  • the NKX6.3 protein according to the present invention may preferably be a functional equivalent to the polypeptide having the amino acid sequence of SEQ ID NO: 1.
  • the term 'functional equivalent' refers to a sequence homology of at least 70%, preferably 70%, more preferably 80% or more with the amino acid sequence represented by SEQ ID NO: 1 as a result of the addition, substitution, or deletion of amino acids. It refers to a polypeptide that exhibits substantially homogeneous activity with NKX6.3 of the present invention.
  • substantially homogeneous activity means the activity of NKX6.3 described above.
  • Such functional equivalents may include, for example, amino acid sequence variants in which some of the amino acids of the amino acid sequence of NKX6.3 according to the invention have been substituted, deleted or added.
  • Substitution of amino acids may preferably be conservative substitutions, examples of conservative substitutions of amino acids present in nature are as follows; Aliphatic amino acids (Gly, Ala, Pro), hydrophobic amino acids (Ile, Leu, Val), aromatic amino acids (Phe, Tyr, Trp), acidic amino acids (Asp, Glu), basic amino acids (His, Lys, Arg, Gln, Asn ) And sulfur-containing amino acids (Cys, Met). Deletion of amino acids may preferably be located at portions not directly involved in the activity of NKX6.3 of the present invention.
  • the functional equivalent may also include polypeptide derivatives in which some chemical structures of the polypeptide are modified while maintaining the basic backbone of NKX6.3 and its physiological activity.
  • polypeptide derivatives in which some chemical structures of the polypeptide are modified while maintaining the basic backbone of NKX6.3 and its physiological activity.
  • fusion proteins made by fusion with other proteins while maintaining structural changes and physiological activities for altering the stability, storage, volatility or solubility of the polypeptide of the present invention may be included.
  • polynucleotide encoding the NKX6.3 protein may be introduced into an expression vector, such as a plasmid or viral vector, by a known method, followed by transduction or transfection of the expression vector by various methods known in the art. transfection) can be introduced into the target cell in the phenotype.
  • an expression vector such as a plasmid or viral vector
  • Plasmid expression vectors are FDA's approved gene delivery methods for human use and deliver plasmid DNA directly to human cells (Nabel, EG et al., Science, 249: 1285-1288, 1990). Unlike viral vectors, there is an advantage that can be purified homogeneously.
  • the plasmid expression vector that can be used in the present invention mammalian expression plasmids known in the art can be used, and in one embodiment of the present invention, the NKX6.3 gene is inserted using a pcDNA3.1 (Invitrogen) plasmid.
  • a recombinant expression vector pcDNA3.1-NKX6.3 having a cleavage map of 12 was prepared.
  • Plasmid expression vectors comprising nucleic acids according to the present invention are methods known in the art, such as, but not limited to, transient transfection, microinjection, transduction, Cell fusion, calcium phosphate precipitation, liposome-mediated transfection, DEAE Dextran-mediated transfection, polybrene-mediated transfection Can be introduced into tumor cells by electroporation, gene guns and other known methods for introducing DNA into cells (Wu. Et al., J. Bio. Chem., 267: 963-967, 1992; Wu. Et al., Bio. Chem., 263: 14621-14624, 1988).
  • transient transfection methods can be used.
  • the vector capable of expressing NKX6.3 may be administered to cells, tissues or the body by known methods, for example, topically, parenteral, oral, nasal, intravenous, intramuscular, subcutaneous. Or by other suitable means.
  • the vector can be injected directly into a target cancer or tumor cell in an effective amount for treating tumor cells of the target tissue.
  • the pharmaceutical composition of the present invention may be used as a hollow organ affected by cancer or a tumor. It can be injected directly using a needle, catheter or other type of transport tube within.
  • the anticancer composition according to the present invention can be used as a pharmaceutical composition that can prevent and treat cancer
  • the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable refers to a composition that is physiologically acceptable and that, when administered to a human, typically does not cause allergic or similar reactions, such as gastrointestinal disorders, dizziness, and the like.
  • Pharmaceutically acceptable carriers include, for example, carriers for oral administration such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid and the like, and parenteral administration such as water, suitable oils, saline, aqueous glucose and glycols, and the like. And the like may further comprise stabilizers and preservatives.
  • Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid.
  • Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol.
  • Other pharmaceutically acceptable carriers may be referred to those described in the following documents (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).
  • the pharmaceutical composition according to the present invention may be formulated in a suitable form according to methods known in the art together with the pharmaceutically acceptable carrier as described above.
  • the pharmaceutical composition of the present invention can be prepared in various parenteral or oral dosage forms according to known methods, and isotonic aqueous solution or suspension is preferable as an injectable formulation as a typical parenteral dosage form.
  • injectable formulations may be prepared according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • each component may be formulated for injection by dissolving in saline or buffer.
  • formulations for oral administration include, but are not limited to, powders, granules, tablets, pills and capsules.
  • compositions formulated in such a manner can be administered in a effective amount via several routes, including oral, transdermal, subcutaneous, intravenous or intramuscular.
  • the term 'effective amount' refers to an amount exhibiting a prophylactic or therapeutic effect when administered to a patient.
  • the dosage of the pharmaceutical composition according to the present invention may be appropriately selected depending on the route of administration, subject to administration, age, gender weight, individual difference and disease state.
  • the pharmaceutical composition of the present invention may vary the content of the active ingredient according to the degree of disease, preferably 1 ⁇ g to 10000 ⁇ g mg / kg body weight / day, more preferably 10 to 1000 ⁇ g / It may be administered repeatedly several times a day at an effective dose of kg / day body weight.
  • the anticancer composition of the present invention may be administered in parallel with a known compound having the effect of preventing, improving or treating cancer.
  • the present invention provides an amount of expression of NKX6.3 protein, an expression amount of mRNA encoding NKX6.3 protein or NKX6 protein in a biological sample taken from a subject to provide information necessary for cancer prevention, diagnosis or prognostic analysis.
  • the method of diagnosing cancer can be provided by checking the DNA copy number of the 3 gene.
  • prevention in the context of the present invention encompasses the prevention of cancer development in precancerous lesions of cancer.
  • prevention in the present invention means the possibility of fundamentally inhibiting the occurrence of cancer.
  • diagnosis refers to determining the susceptibility of an object to a particular disease or condition, determining whether an object currently has a particular disease or condition, a particular disease or condition Determining the prognosis (eg, identifying a metastatic or metastatic cancer state, determining the stage of the cancer, or determining the responsiveness of the cancer to treatment), or therametrics (eg, treatment) Monitoring the state of the object to provide information about its efficacy.
  • prognosis eg, identifying a metastatic or metastatic cancer state, determining the stage of the cancer, or determining the responsiveness of the cancer to treatment
  • therametrics eg, treatment
  • prognosis in the context of the present invention includes the prediction in terms of the process of disease progression, in particular, the degree of disease remission, disease regeneration, tumor recurrence, metastasis and death.
  • the prognosis in the present invention means the possibility that the disease of a cancer patient will be cured.
  • the high malignancy of cancer in the present invention includes a state of high invasion and metastasis of cancer and a high risk of recurrence.
  • the present invention can be carried out by immunoassay (ie, antigen-antibody reaction).
  • immunoassay ie, antigen-antibody reaction
  • the antibody or aptamer specifically binds to the cancer marker of the present invention described above.
  • the antibody used in the present invention is a polyclonal or monoclonal antibody, preferably a monoclonal antibody.
  • Antibodies may be commonly used in the art, such as fusion methods (Kohler and Milstein, European Journal of Immunology, 6: 511-519 (1976)), recombinant DNA methods (US Pat. No. 4,816,56) Or phage antibody library methods (Clackson et al, Nature, 352: 624-628 (1991) and Marks et al, J. Mol. Biol., 222: 58, 1-597 (1991)). General procedures for antibody preparation are described in Harlow, E.
  • the present invention can be used to diagnose cancer by performing according to conventional immunoassay methods.
  • immunoassays can be performed according to various quantitative or qualitative immunoassay protocols developed in the prior art.
  • the immunoassay format may include radioimmunoassay, radioimmunoprecipitation, immunoprecipitation, immunohistochemical staining, enzyme-linked immunosorbant assay (ELISA), capture-ELISA, inhibition or hardwood analysis, sandwich analysis, flow cytometry, immunoassay. Including but not limited to fluorescent staining and immunoaffinity purification.
  • the immunoassay or method of immunostaining is described in Enzyme Immunoassay, E. T.
  • antibodies labeled with radioisotopes eg, C14, I125, P32 and S35
  • radioisotopes eg, C14, I125, P32 and S35
  • certain embodiments of the present invention comprise the steps of: (1) coating an unknown cell sample lysate to be analyzed on the surface of a solid substrate; (2) reacting the cell lysate with an antibody to a marker as a primary antibody; (3) reacting the resultant of step (2) with a secondary antibody to which an enzyme is bound; And (4) measuring the activity of the enzyme.
  • Suitable as the solid substrate are hydrocarbon polymers (eg polystyrene and polypropylene), glass, metal or gel, most preferably microtiter plates.
  • Enzymes bound to the secondary antibody include, but are not limited to, enzymes catalyzing color reaction, fluorescence, luminescence or infrared reaction, for example, alkaline phosphatase, ⁇ -galactosidase, hose Radish peroxidase, luciferase and cytochrome P450.
  • alkaline phosphatase When alkaline phosphatase is used as the enzyme binding to the secondary antibody, bromochloroindolyl phosphate (BCIP), nitro blue tetrazolium (NBT), naphthol-AS-B1-phosphate (naphthol-AS) as a substrate Chloronaphthol, aminoethylcarbazole, diaminobenzidine, D-luciferin, lucigenin (bis) when chromogenic reaction substrates such as -B1-phosphate) and enhanced chemifluorescence (ECF) are used, and horse radish peroxidase is used -N-methylacridinium nitrate), lesoruppin benzyl ether, luminol, Amflex Red reagent (10-acetyl-3,7-dihydroxyphenoxazine), p-phenylenediamine-HCl and pyrocatechol (HYR), TMB (tetramethylbenz
  • certain embodiments of the invention comprise the steps of: (1) coating the surface of a solid substrate with an antibody against the marker of the invention as a capturing antibody; (2) reacting the capture antibody with the sample; (3) reacting the resultant of step (2) with a detecting antibody which has a label generating a signal and which specifically reacts with NKX6.3 protein; And (4) measuring the signal resulting from the label.
  • the detection antibody carries a label which generates a detectable signal.
  • the label may include chemicals (eg biotin), enzymes (alkaline phosphatase, ⁇ -galactosidase, horse radish peroxidase and cytochrome P450), radioactive substances (eg C14, I125, P32 and S35) , Fluorescent materials (eg, fluorescein), luminescent materials, chemiluminescent, and fluorescence resonance energy transfer (FRET).
  • chemicals eg biotin
  • enzymes alkaline phosphatase, ⁇ -galactosidase, horse radish peroxidase and cytochrome P450
  • radioactive substances eg C14, I125, P32 and S35
  • Fluorescent materials eg, fluorescein
  • luminescent materials eg, chemiluminescent
  • FRET fluorescence resonance energy transfer
  • Measurement of the final enzyme activity or signal in the ELISA method and the capture-ELISA method can be carried out according to various methods known in the art. Detection of such signals allows for qualitative or quantitative analysis of the markers of the invention. If biotin is used as a label, the signal can be easily detected with streptavidin and luciferin if luciferase is used.
  • an aptamer that specifically binds to the marker of the present invention may be used instead of the antibody.
  • Aptamers are oligonucleic acid or peptide molecules, the general contents of which are described in Bock LC et al., Nature 355 (6360): 5646 (1992); Hoppe-Seyler F, Butz K "Peptide aptamers: powerful new tools for molecular medicine”. J Mol Med. 78 (8): 42630 (2000); Cohen BA, Colas P, Brent R. "An artificial cell-cycle inhibitor isolated from a combinatorial library”. Proc Natl Acad Sci USA. 95 (24): 142727 (1998).
  • Cancer can be diagnosed by analyzing the final signal intensity by the above-described immunoassay process. That is, if the protein of the marker of the present invention is low in the biological sample and the signal is significantly weaker than the normal biological sample (eg, normal gastric tissue, blood, plasma or serum), the cancer may be diagnosed.
  • the normal biological sample eg, normal gastric tissue, blood, plasma or serum
  • the present invention can diagnose cancer by confirming the expression amount of mRNA encoding the NKX6.3 protein or the DNA copy number of the NKX6.3 gene.
  • the amount of mRNA expression or DNA copy number of the NKX6.3 gene can be confirmed by PCR amplification, and can be confirmed by microarray.
  • amplification means a reaction that amplifies a nucleic acid molecule.
  • Various amplification reactions have been reported in the art, which include polymerase chain reaction (PCR) (US Pat. Nos. 4,683,195, 4,683,202, and 4,800,159), reverse transcriptase-polymerase chain reaction (RT-PCR) (Sambrook et al., Molecular Cloning. A Laboratory Manual, 3rd ed.Cold Spring Harbor Press (2001)), Miller, HI (WO 89/06700) and Davey, C. et al.
  • PCR polymerase chain reaction
  • RT-PCR reverse transcriptase-polymerase chain reaction
  • PCR is the best known nucleic acid amplification method, and many modifications and applications thereof have been developed. For example, touchdown PCR, hot start PCR, nested PCR, and booster PCR have been developed by modifying traditional PCR procedures to enhance the specificity or sensitivity of PCR.
  • real-time PCR differential display PCR (DD-PCR), rapid amplification of cDNA ends (RACE), multiplex PCR, inverse polymerase chain reaction (inverse polymerase) chain reaction (IPCR), vectorette PCR and thermal asymmetric interlaced PCR (TAIL-PCR) have been developed for specific applications.
  • DD-PCR differential display PCR
  • RACE rapid amplification of cDNA ends
  • IPCR inverse polymerase chain reaction
  • TAIL-PCR thermal asymmetric interlaced PCR
  • the probe or primer used for diagnosis in the present invention has a sequence complementary to the NKX6.3 nucleotide sequence.
  • the term “complementary” means having complementarity sufficient to selectively hybridize to the above-described nucleotide sequence under certain specific hybridization or annealing conditions.
  • the term complementary has a meaning different from that of the term perfectly complementary, and the primers or probes of the present invention may be capable of selectively hybridizing to the above-described nucleotide sequence, so long as one or more mismatch bases are used. May have a sequence.
  • primer refers to a single that can act as an initiation point for template-directed DNA synthesis under suitable conditions (ie, four different nucleoside triphosphates and polymerases) in a suitable buffer at a suitable temperature. -Refers to stranded oligonucleotides. Suitable lengths of primers are typically 15-30 nucleotides, although varying with various factors, such as temperature and the use of the primer. Short primer molecules generally require lower temperatures to form hybrid complexes that are sufficiently stable with the template.
  • the sequence of the primer does not need to have a sequence that is completely complementary to some sequences of the template, and it is sufficient to have sufficient complementarity within a range capable of hybridizing with the template to perform the primer-specific function. Therefore, the primer in the present invention does not need to have a sequence that is perfectly complementary to the above-described nucleotide sequence as a template, and it is sufficient to have sufficient complementarity within a range capable of hybridizing to the gene sequence and acting as a primer.
  • the design of such primers can be easily carried out by those skilled in the art with reference to the above-described nucleotide sequence, for example, by using a program for primer design (eg, PRIMER 3 program).
  • probe refers to a linear oligomer of natural or modified monomers or linkages, includes deoxyribonucleotides and ribonucleotides, and can specifically hybridize to a target nucleotide sequence, naturally Present or artificially synthesized. Probes of the invention are preferably single chain and oligo deoxyribonucleotides.
  • the label of the probe can provide a signal that allows detection of hybridization, which can be linked to oligonucleotides.
  • Suitable labels include fluorophores (eg fluorescein, phycoerythrin, rhodamine, lissamine, and Cy3 and Cy5 (Pharmacia), chromophores, chemilumines, magnetic particles, radioisotopes Elements (P32 and S35), mass labels, electron dense particles, enzymes (alkaline phosphatase or horseradish peroxidase), cofactors, substrates for enzymes, heavy metals (eg gold) and antibodies, streptavidin, biotin And hapten with specific binding partners such as digoxigenin and chelating groups.
  • fluorophores eg fluorescein, phycoerythrin, rhodamine, lissamine, and Cy3 and Cy5 (Pharmacia)
  • chromophores eg fluorescein, phyco
  • Labeling is carried out in a variety of ways conventionally practiced in the art, such as nick translation methods, random priming methods (Multiprime DNA labeling systems booklet, "Amersham” (1989)) and chination methods (Maxam & Gilbert, Methods). in Enzymology, 65: 499 (1986)). Labels provide signals detectable by fluorescence, radioactivity, colorimetry, gravimetric, X-ray diffraction or absorption, magnetism, enzymatic activity, mass analysis, binding affinity, hybridization high frequency, nanocrystals.
  • the nucleic acid sample to be analyzed may be prepared using mRNA obtained from various biological samples, and preferably, may be prepared using mRNA obtained from stomach tissue cells.
  • the hybridization reaction-based assay may be performed by labeling the cDNA to be analyzed instead of the probe.
  • NKX6.3 of the present invention has the activity of inhibiting the proliferation of cancer cells and promote cell death, the present invention can provide an anticancer screening method using the gene.
  • the anticancer drug screening method according to the present invention may include the step of measuring the effect on the activity of NKX6.3 protein or increase in the expression level of cells by treating the anticancer agent candidate cells.
  • the candidate substance increases the activity of the NKX6.3 protein or increases the expression level of the NKX6.3 gene in the cell, it may further comprise the step of judging it as an anticancer agent having anticancer activity.
  • the increase in the activity or expression level of the NKX6.3 protein in the cell means that the expression of the NKX6.3 gene is increased or the degradation of the NKX6.3 protein is inhibited, thereby increasing the concentration of the NKX6.3 protein.
  • the NKX6.3 gene expression includes the transcription and translation of the NKX6.3 gene into protein.
  • NKX6.3 protein activity or intracellular expression level may be measured by immunoprecipitation, radioimmunoassay (RIA), enzyme immunoassay (ELISA), immunohistochemistry, polymerase chain reaction (PCR), and Western blotting. (Western Blotting) and flow cytometry (FACS) can be performed by any one method selected from the group consisting of.
  • RIA radioimmunoassay
  • ELISA enzyme immunoassay
  • PCR polymerase chain reaction
  • FACS flow cytometry
  • the screening method targeting NKX6.3 of the present invention can apply high throughput screening (HTS).
  • HTS is a method of testing multiple candidates in parallel and screening simultaneously or nearly simultaneously for the biological activity of the multiple candidates.
  • cell lines can be cultured in 96-well microtiter plates or 192-well microtiter plates, treated with a number of candidates therein and then the level of expression of NKX6.3 can be measured by immunochemical methods.
  • the wells typically require assay volumes ranging from 50 ⁇ l to 500 ⁇ l and, in addition to plates, a number of instruments, instruments, pipettes, robots, robots, etc., to suit 96-well formats for a wide range of homogeneous and heterogeneous assays. Plate washers and plate readers are commercially available.
  • AGS, MKN1, MKN28 and MNK45 gastric cancer cell lines were incubated at 37% in 5% CO 2 using RPMI-1640 medium with 10% FBS inactivated by heat. After cloning the entire NKX6.3-cDNA into the pcDNA3.1 (Invitrogen, Carlsbad, CA, USA) expression vector, Lipofectamine Plus transfection reagent (Invitrogen) was applied to AGS and MKN1 cell lines in total 5 mg of the expression plasmid in 60 mm dishes. was temporarily transfected according to the manufacturer's method.
  • AGS and MKN1 cell lines AGS NKX6.3 and MNK1 NKX6.3 cell lines stably expressing human NKX6.3 were prepared, and stable NKX6.3 protein expression was confirmed by Western blot.
  • NKX6.3 protein was examined by Western blotting on gastric cancer tissues collected from the 35 patients, and the expression level of NKX6.3 in non-cancerous-gastrointestinal mucosa tissues corresponding to each example was also examined.
  • Gastric cancer cell lines such as AGS, MKN1, MKN28, and MNK45 were also examined for expression levels of NKX6.3.
  • Cells were lysed for western blotting, electrophoresed on 20% polyacrylamide gels, then transferred to Hybond-PVDF membranes (Bio-Rad, Hercules, Calif., USA) and anti-NKX6.3 monoclones. Reaction with antibody (Abcam, Cambridge, UK). Protein bands were detected with ECM Western Blotting Detection Reagent (Bid-Rad).
  • NKX6.3 protein was not observed in AGS, MNK1, MKN28 and MKN45 gastric cancer cell lines, and it was confirmed that NKX6.3 was completely inactivated in these gastric cancer cell lines (see FIG. 1A).
  • NKX6.3 was completely inactivated in these gastric cancer cell lines.
  • FIG. 1B In 35 samples of non-cancerous gastric mucosa tissue including the upper [cardia], middle [fundus, corpus], and lower [antrum and pylorus] Expression of the NKX6.3 protein was confirmed, and in 33 (94.3%) of these gastric cancer tissues, the expression was found to be lost or decreased (see FIG. 1B).
  • NKX6.3 of Example 2 was associated with mutation of the gene.
  • genomic DNA from each tumor cell and corresponding non-cancerous gastric mucosa cells was amplified with six sets of primers covering the entire coding region of the NKX6.3 gene.
  • Specific primers for detecting mutations of NKX6.3 include GenBank accession No. Designed according to the genome sequence of NC_000008.11, specific primer sequences are shown in Table 1 below.
  • PCR polymerase chain reaction
  • NKX6.3 of Example 2 was determined by methylation of the promoter region of the NXK6.3 gene.
  • the methylation status of the promoter region of the NKX6.3 gene was measured by methylation specific PCR (MSP) after sodium hydrogen sulfite treatment on DNA. 5 ⁇ l of disulfate modified DNA was MSP using two sets of NKX6.3 primers for analyzing methylated or unmethylated NKX6.3. Primers used at this time are shown in Table 1 above.
  • PCR was performed in a total volume of 30 ⁇ l using 5 ⁇ l template DNA, 0.5 ⁇ M of each primer, 0.2 ⁇ M of each dNTP, 1.5 mM MgCl 2 , 0.4 unit of Ampli Taq gold polymerase (Perkin-Elmer), and 3 ⁇ l 10 ⁇ buffer. .
  • the reaction solution was initially denatured at 95 ° C. for 1 minute.
  • Amplification was carried out for 40 seconds for 30 seconds at 95 ° C, 30 seconds at 59 ° C, and 30 seconds at 72 ° C, and further extended for 5 minutes at 72 ° C.
  • PCR products were directly electrophoresed on 2% agarose gels, stained with EtBr and confirmed by UV illumination.
  • NKX6.3 methylation and unmethylation of the NKX6.3 gene was shown in all normal and gastric cancer tissues (see FIG. 1C), so that specific methylation of NKX6.3 did not affect NKX6.3 expression in gastric cancer tissues.
  • FIG. 1C shows that specific methylation of NKX6.3 did not affect NKX6.3 expression in gastric cancer tissues.
  • NKX6.3 The aim of this study was to determine whether the decrease in the expression level of NKX6.3 is related to the change of DNA copy number and mRNA expression of NKX6.3.
  • genomic DNA and mRNA were extracted and quantified from gastric cancer tissues and corresponding non-cancerous gastric mucosal tissues, and then real-time SYBR Green QPCR was performed using the Stratagene Mx 3000P QPCR system. Specific primers for confirming NKX6.3 DNA copy number are described in Genbank accession No. It was designed using the genomic sequence of NC_000008.11. All samples were normalized by PCR amplification with GAPDH specific primers. Primers for SYBR Green analysis were designed based on gene specific gene-specific non-homologous DNA sequences, primer sequences as described in Table 1 above.
  • cDNA was synthesized according to the manufacturer's method using a reverse transcription kit manufactured by Roche Molecular System (Roche, Mannheim, Germany).
  • 50ng of cDNA was amplified with the Stratagene Mx 3000P QPCR system using Fullvelocity SYBR Green QPCR Master Mix (Stratagene, La Jolla, Calif., USA) and 20 pmol / ⁇ l forward and reverse primers.
  • NKX6.3 DNA copy number of NKX6.3 was found to be reduced in 18 gastric cancer DNAs compared to the gastric mucosal DNA in the periphery thereof (see FIG. 2A).
  • the NKX6.3 gene transcript was expressed in non-cancerous gastric mucosal tissue corresponding to all examples (see FIG. 2B). Loss or decrease in the expression of mRNA transcripts was observed in 34 (61.8%) of the 55 gastric cancer tissues analyzed. In both non-cancerous gastric mucosal and gastric cancer tissues, there was a significant correlation between DNA copy number and mRNA transcript expression of NKX6.3 (P ⁇ 0.0001) (see Figures 2C and 2D).
  • NKX6.3 The mRNA expression level of NKX6.3 was examined in 55 stomach tissues by real-time RT-PCR analysis.
  • NKX6.3 mRNA expression of NKX6.3 was decreased in 28 tissues (50.9%).
  • ROC curve analysis was performed using NKX6.3.
  • ROC curve analysis was performed using Cdx2 to distinguish atrophic gastritis or enteroplasia from human gastric mucosal tissue.
  • NKX6.3 is decreased and the expression of Cdx2 is increased in atrophic gastritis or intestinal metaplasia stages before cancer development, atrophic gastritis, a lesion before developing cancer Increasing the expression of NKX6.3 or reducing the expression of Cdx2 in the intestinal metaplasia phase was able to prevent the occurrence of cancer.
  • NKX6.3 was stably expressed in AGS and MKN1 cell lines.
  • NKX6.3 acts as a transcription factor of Sox2, a gastric differentiation marker, and Cdx2, an intestinal differentiation marker, to control expression by Chromatin immunoprecipitation-PCR. It was.
  • NKX6.3 induces expression of gastric differentiation marker Sox2 and inhibits the expression of intestinal differentiation marker Cdx2 as a transcription factor that binds to promoter regions of Sox2 and Cdx2 genes (see FIG. 4).
  • normal gastric gland in human gastric mucosal tissues expresses NKX6.3, Sox2 and Muc5ac, but gastric gland with intestinal metaplasia is lost in their expression and intestinal differentiation markers Cdx2 and Muc2 are expressed. The results of the study were verified (see FIG. 5).
  • NKX6.3 in gastric epithelial cells, it was possible to stably express NKX6.3 in AGS and MKN1 cell lines.
  • Production and MNK1 AGS cell line AGS stably expressing the NKX6.3 and NKX6.3 cell lines MNK1 NKX6.3 sepojueul To this end, and to prepare a mock AGS and MNK1 mock cell line, the control for this.
  • Stable expression of NKX6.3 in AGS NB6.3 NKX6.3 and MNK1 NB6.3 cell lines was confirmed by Western blotting.
  • the AGS NB6.3 and MNK1 NB6.3 cell lines were found to stably express NKX6.3 protein as compared to the control group.
  • NKX6.3 is to analyze the effect on cell viability, MTT [3- (4,5 dimethylthiazol- 2-yl -2,5-diphenyltetrazoliumbromide] by a method AGS mock, mock MNK1, AGS NKX6.3 Cell viability was analyzed at 24, 48 and 72 hours in MNK1 and NNK6.3 cell lines, and absorbance was measured using a spectrophotometer at 540 nm, and cell viability was observed relative to mock (empty vector + lipofectamine). .
  • NKX6.3 significantly inhibited the survival of the gastric cancer cells over time in the AGS Nv6.3 and MNK1 Nv6.3 cell lines compared to the control group (see FIG. 6A).
  • NKX6.3 significantly inhibited the proliferation of gastric cancer cells over time and colony formation compared to the control group (see FIGS. 6B and 5C).
  • NKX6.3 inhibited cell cycle progression in AGS N6.3 and MNK1 N6.3 cell lines (see FIG. 6D).
  • NKX6.3 To determine if cell death was induced in NKX6.3, the cells were stained by FITC-labeled annexin V staining in the AGS NB6.3 and MNK1 NB6.3 cell lines stably expressing NKX6.3. Cell death was analyzed. To this end, Annexin V-binding assay was performed at 24, 48 and 72 hours after incubation in AGS N6.3 and MNK1 N6.3 cell lines according to the manufacturer's method.
  • the AGS NB6.3 and MNK1 NB6.3 cell lines were washed twice with cold PBS, resuspended using 100 ⁇ L binding buffer, and then 100 ⁇ L of the supernatant was mixed with 400 ⁇ L of blocking solution, 5 ⁇ l (1 ⁇ g / ml) of annexin V-FITC and 5 ⁇ l of PI (2 ⁇ g / ml) were added to the mixed solution and reacted in the dark for 15 minutes. Cells were then analyzed by flow cytometry (FACS, BD Biosciences, San Jose, Calif., USA) and only fluorescence-positive cells without PI staining were considered dead cells.
  • flow cytometry FACS, BD Biosciences, San Jose, Calif., USA
  • NKX6.3 is specifically reduced in gastric cancer cells, and when NKX6.3 is introduced into such gastric cancer cell line, the gastric cancer cell line specifically inhibits cell proliferation and induces cell death. As can be seen, it was found that NKX6.3 can be treated with gastric cancer treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation de NKX6.3 pour la prévision de l'apparition d'un cancer et le diagnostic précoce du cancer et en tant qu'agent thérapeutique pour le cancer et, plus spécifiquement, une utilisation de NKX6.3 pour la prévision de l'apparition d'un cancer et le diagnostic précoce du cancer sur la base du niveau d'expression de la protéine NKX6.3, le niveau d'expression de l'ARNm, et le nombre de copies d'ADN, et pour la prévention et le traitement du cancer par administration d'une protéine NKX6.3 ou d'un gène de NKX6.3. NKX6.3 selon la présente invention peut être utilisée en tant que composition de diagnostic pour le diagnostic précoce du cancer car son activité ou son expression est inhibée dans une cellule cancéreuse. En outre, NKX6.3 exerce les fonctions d'inhibition de la survie et de la prolifération des cellules cancéreuses et d'induction de l'apoptose lorsque son expression est induite, et peut donc être avantageusement utilisée en tant que composition de traitement anticancéreux.
PCT/KR2015/005013 2014-05-19 2015-05-19 Utilisation de nkx6.3 pour la prévision de l'apparition du cancer et le diagnostic précoce d'un cancer et en tant qu'agent thérapeutique pour le cancer Ceased WO2015178667A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2016568505A JP6312861B2 (ja) 2014-05-19 2015-05-19 がん発症の予測、早期診断、及び治療剤としてのｎｋｘ６．３の用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2014-0059484 2014-05-19
KR20140059484 2014-05-19
KR10-2015-0069359 2015-05-19
KR1020150069359A KR101722836B1 (ko) 2014-05-19 2015-05-19 암 발병의 예측, 조기 진단 및 치료제로써의 nkx6.3의 용도

Publications (1)

Publication Number Publication Date
WO2015178667A1 true WO2015178667A1 (fr) 2015-11-26

Family

ID=54554268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/005013 Ceased WO2015178667A1 (fr) 2014-05-19 2015-05-19 Utilisation de nkx6.3 pour la prévision de l'apparition du cancer et le diagnostic précoce d'un cancer et en tant qu'agent thérapeutique pour le cancer

Country Status (1)

Country Link
WO (1) WO2015178667A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110152106A1 (en) * 2008-04-21 2011-06-23 Korea Research Institute Of Bioscience And Biotechnology Cst1, dcc1, ifitm1 or melk as markers for diagnosing stomach cancer
WO2012031008A2 (fr) * 2010-08-31 2012-03-08 The General Hospital Corporation Matières biologiques liées au cancer dans des microvésicules
US20120230952A1 (en) * 2011-03-11 2012-09-13 Woonbok Chung Detection of bladder cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110152106A1 (en) * 2008-04-21 2011-06-23 Korea Research Institute Of Bioscience And Biotechnology Cst1, dcc1, ifitm1 or melk as markers for diagnosing stomach cancer
WO2012031008A2 (fr) * 2010-08-31 2012-03-08 The General Hospital Corporation Matières biologiques liées au cancer dans des microvésicules
US20120230952A1 (en) * 2011-03-11 2012-09-13 Woonbok Chung Detection of bladder cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHOI ET AL.: "Requirement of the tissue-restricted homeodomain transcription factor Nkx6. 3 in differentiation of gastrin-producing G cells in the stomach antrum", MOLECULAR AND CELLULAR BIOLOGY, vol. 28, no. 10, 2008, pages 3208 - 3218, XP055238128, ISSN: 0270-7306 *
HAFLER ET AL.: "Expression and function of Nkx6.3 in vertebrate hindbrain", BRAIN RESEARCH, vol. 1222, 2008, pages 42 - 50, XP022850470, ISSN: 0006-8993 *
KOBAYASHI ET AL.: "Suppressor of cytokine signaling 4 detected as a novel gastric cancer suppressor gene using double combination array analysis", WORLD JOURNAL OF SURGERY, vol. 36, no. 2, 2012, pages 362 - 372, XP035000216, ISSN: 1432-2323 *
PARK ET AL.: "Aberrant expression of SOX2 upregulates MUC5AC gastric foveolar mucin in mucinous cancers of the colorectum and related lesions", INTERNATIONAL JOURNAL OF CANCER, vol. 122, no. 6, 2008, pages 1253 - 1260, XP055238129, ISSN: 0020-7136 *
ROESSLER ET AL.: "Co-expression of CDX2 and MUC2 in gastric carcinomas: correlations with clinico-pathological parameters and prognosis", WORLD JOURNAL OF GASTROENTEROLOGY, vol. 11, no. 21, 2005, pages 3182 - 3188, XP055238131, ISSN: 1007-9327 *

Similar Documents

Publication Publication Date Title
IL200908A (en) Methods for classification of endometrial cancer and preparations for its treatment
WO2009113814A2 (fr) Marqueur protéique utilisé pour le diagnostic précoce du cancer du foie
WO2012064146A2 (fr) Composition anticancéreuse contenant gkn 1
WO2017222221A1 (fr) Composition pour le diagnostic du cancer utilisant des protéines de canal potassique
Dong et al. Downregulation of HTATIP2 expression is associated with promoter methylation and poor prognosis in glioma
Liu et al. Jumonji domain-containing protein 1A promotes cell growth and progression via transactivation of c-Myc expression and predicts a poor prognosis in cervical cancer
Smith et al. The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role
WO2017026843A1 (fr) Procédé de fourniture d'informations sur la leucémie myéloïde chronique
WO2016152352A1 (fr) Biomarqueur spécifique du mélanome et son utilisation
WO2011081421A2 (fr) C9 du complément comme marqueur pour le diagnostic d'un cancer
Fang et al. Caspase-14 is an anti-apoptotic protein targeting apoptosis-inducing factor in lung adenocarcinomas
KR101058753B1 (ko) 대장암 마커로서의 ｅｓｍ－１ 유전자 및 이를 이용한대장암의 진단 및 치료에의 용도
Jonckheere et al. The mouse Muc5b mucin gene is transcriptionally regulated by thyroid transcription factor‐1 (TTF‐1) and GATA‐6 transcription factors
US20130217046A1 (en) Method for determining predisposition to esophageal-related disorders
KR101722836B1 (ko) 암 발병의 예측, 조기 진단 및 치료제로써의 nkx6.3의 용도
WO2014014157A1 (fr) Utilisation de l'adcy3 pour diagnostiquer et traiter le cancer de l'estomac
Cai et al. RING domain of zinc finger protein like 1 is essential for cell proliferation in endometrial cancer cell line RL95-2
WO2015178667A1 (fr) Utilisation de nkx6.3 pour la prévision de l'apparition du cancer et le diagnostic précoce d'un cancer et en tant qu'agent thérapeutique pour le cancer
Aurrière et al. Cancer/Testis Antigen 55 is required for cancer cell proliferation and mitochondrial DNA maintenance
WO2023085716A1 (fr) Protéine à haute affinité atp comme cible thérapeutique pour des sous-types moléculaires de cancer réfractaires et son inhibiteur
WO2009131366A2 (fr) Cdca5 en tant que marqueur diagnostique et agent thérapeutique pour le cancer gastrique ou le cancer colorectal
US20150354006A1 (en) Markers for acute lymphoblastic leukemia
WO2016200246A1 (fr) Nouveau biomarqueur de diagnostic d'une résistance à un agent anticancéreux pour un cancer du tractus biliaire, et utilisation correspondante
US20080219981A1 (en) Diagnostic Kit for Solid Cancer and Medicament for Solid Cancer Therapy
WO2022019626A1 (fr) Procédé de criblage d'inhibiteur de métastase du cancer colorectal

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15796906

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016568505

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15796906

Country of ref document: EP

Kind code of ref document: A1